Short course of R-HyperCVAD/MTX/ARA-C followed by ASCT as...

Hematological Oncology 2017 / 06 Vol. 35

Short course of R-HyperCVAD/MTX/ARA-C followed by ASCT as first-line therapy in mantle cell lymphoma patients prolongs progression-free survival to more than 9 years

Andrade Campos, M., Mercadal, S., Domingo Domenech, E., Paredes, V., Aguilera, C., Oliveira, A., de la Banda, E., Climent, F., Parody, R., Fernandez de Sevilla, A., Sureda, A., Gonzalez Barca, E.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
35
Language:
english
Journal:
Hematological Oncology
DOI:
10.1002/hon.2439_113
Date:
June, 2017
File:
PDF, 138 KB
english, 2017
Conversion to is in progress
Conversion to is failed